NCT00113035View on ClinicalTrials.gov

Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2005

Study Completion Date

October 31, 2005

Conditions

Pompe Disease

Trial Locations (5)

10029

Mount Sinai School of Medicine, New York

15213

University of Pittsburgh Medical Center, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

63110

Washington University Medical Center, St Louis

90211

Tower Hematology/Oncology Medical Group, Beverly Hills

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00113035 - Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease | Biotech Hunter | Biotech Hunter